21 CFR Part 11 Compliance Consulting Services

Yes, if electronic signatures are used in place of handwritten signatures for FDA-regulated records, they must meet 21 CFR Part 11 requirements. That typically includes unique user identification, secure authentication, signature controls, audit trail support, and documented procedures linking the signature to its meaning, such as review, approval, or authorization. The surrounding system and records process must also be compliant.

21 CFR Part 11 applies to organizations that create, modify, maintain, archive, retrieve, or transmit electronic records required by FDA regulations, and to those using electronic signatures in FDA-regulated activities. This often includes medical device companies, pharmaceutical manufacturers, biotech firms, clinical laboratories, diagnostic companies, and software-enabled regulated operations supporting quality, manufacturing, testing, or submissions.

Part 11 consulting typically includes gap assessments, system and procedure reviews, validation strategy support, audit trail and access control evaluation, electronic signature controls, SOP development, remediation planning, staff training, and audit readiness preparation. Elexes also supports digital transformation projects such as LIMS or ELN implementation where Part 11, ALCOA+, and data integrity requirements must be built into the solution.

A proper assessment reviews both technology and quality processes. Consultants examine system functionality, user roles, audit trails, security controls, record retention, validation evidence, change control, training records, SOPs, and how electronic signatures are applied. The output should identify specific gaps, map them to regulatory expectations, rank risk, and provide a prioritized remediation plan your team can execute.

Yes. FDA expects systems used to create or manage regulated electronic records to be validated for their intended use. Validation should demonstrate that the software performs consistently and reliably in your actual operating environment. This usually includes requirements definition, risk-based testing, IQ/OQ/PQ or equivalent evidence, deviation handling, approval records, and controlled documentation supporting ongoing system use and changes.

In many cases, yes, but the answer depends on the system's technical capabilities and available documentation. Some legacy platforms can be remediated through procedural controls, supplemental validation, access management improvements, and better audit trail governance. Others may require configuration changes, interface controls, or replacement if they cannot support core Part 11 expectations such as secure signatures, traceability, or reliable record integrity.

Timelines vary based on system complexity, number of applications, documentation maturity, and whether remediation is limited or enterprise-wide. A focused assessment may take a few weeks, while broader remediation and validation programs can extend over several months. Projects move faster when requirements, system ownership, SOPs, and validation records are already organized and internal stakeholders are available for timely review and approvals.

Part 11 consulting is commonly needed by medical device manufacturers, pharmaceutical and biotech companies, IVD and diagnostic organizations, digital health teams, clinical and analytical laboratories, and regulated software environments supporting quality or manufacturing. Any organization using electronic records or signatures in FDA-regulated workflows can benefit from expert review, especially before inspections, software rollouts, or major quality system upgrades.